JP2018502579A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502579A5
JP2018502579A5 JP2017536359A JP2017536359A JP2018502579A5 JP 2018502579 A5 JP2018502579 A5 JP 2018502579A5 JP 2017536359 A JP2017536359 A JP 2017536359A JP 2017536359 A JP2017536359 A JP 2017536359A JP 2018502579 A5 JP2018502579 A5 JP 2018502579A5
Authority
JP
Japan
Prior art keywords
genetically modified
promoter
medical
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017536359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502579A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/050271 external-priority patent/WO2016110565A1/en
Publication of JP2018502579A publication Critical patent/JP2018502579A/ja
Publication of JP2018502579A5 publication Critical patent/JP2018502579A5/ja
Pending legal-status Critical Current

Links

JP2017536359A 2015-01-08 2016-01-08 α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 Pending JP2018502579A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15150454 2015-01-08
EP15150454.5 2015-01-08
EP15191934 2015-10-28
EP15191934.7 2015-10-28
PCT/EP2016/050271 WO2016110565A1 (en) 2015-01-08 2016-01-08 Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020199368A Division JP2021046416A (ja) 2015-01-08 2020-12-01 α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞

Publications (2)

Publication Number Publication Date
JP2018502579A JP2018502579A (ja) 2018-02-01
JP2018502579A5 true JP2018502579A5 (enExample) 2019-02-14

Family

ID=55129837

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017536359A Pending JP2018502579A (ja) 2015-01-08 2016-01-08 α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2020199368A Pending JP2021046416A (ja) 2015-01-08 2020-12-01 α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2022166094A Active JP7374527B2 (ja) 2015-01-08 2022-10-17 α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2023179480A Pending JP2024010006A (ja) 2015-01-08 2023-10-18 α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020199368A Pending JP2021046416A (ja) 2015-01-08 2020-12-01 α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2022166094A Active JP7374527B2 (ja) 2015-01-08 2022-10-17 α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2023179480A Pending JP2024010006A (ja) 2015-01-08 2023-10-18 α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞

Country Status (18)

Country Link
US (3) US20180000969A1 (enExample)
EP (1) EP3242933B1 (enExample)
JP (4) JP2018502579A (enExample)
CN (1) CN107208063A (enExample)
AU (1) AU2016206033B2 (enExample)
CA (1) CA2970993C (enExample)
CY (1) CY1122004T1 (enExample)
DK (1) DK3242933T3 (enExample)
ES (1) ES2727820T3 (enExample)
HU (1) HUE043478T2 (enExample)
IL (1) IL253063B (enExample)
LT (1) LT3242933T (enExample)
PL (1) PL3242933T3 (enExample)
PT (1) PT3242933T (enExample)
RS (1) RS58977B1 (enExample)
SI (1) SI3242933T1 (enExample)
SM (1) SMT201900381T1 (enExample)
WO (1) WO2016110565A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220010281A1 (en) * 2018-10-29 2022-01-13 Ottawa Hospital Research Institute Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
CN109512893A (zh) * 2018-11-05 2019-03-26 北京世纪劲得生物技术有限公司 间充质干细胞及其注射液和组合物在高尿酸血症中的应用
JP7561348B2 (ja) * 2019-07-31 2024-10-04 株式会社ステムリム 間葉系幹細胞の増殖促進または減少抑制のための組成物
WO2021146471A2 (en) * 2020-01-15 2021-07-22 The Regents Of The University Of California Transplanted cell protection via inhibition of polymorphonuclear cells
EP3964265A1 (en) * 2020-09-07 2022-03-09 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
AU2021375735A1 (en) * 2020-11-06 2023-06-08 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
WO2024005157A1 (ja) * 2022-06-30 2024-01-04 国立大学法人熊本大学 脂肪細胞活性化剤
CN116173218B (zh) * 2023-04-28 2023-08-04 北京大学口腔医学院 蛋白转运抑制剂在制备用于治疗或缓解牙周炎的药物中的用途
CN121909290A (zh) * 2023-07-10 2026-04-21 普瑞赛格恩公司 α-1抗胰蛋白酶缺乏症的治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US20070003518A1 (en) * 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US20090324609A1 (en) * 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
EP2793936A4 (en) * 2011-12-19 2015-05-27 Lfb Usa Inc RECOMBINANT HUMAN ALPHA-1-ANTITRYPINE FOR THE TREATMENT OF INFLAMMATORY DISEASES
CN102920735A (zh) * 2012-11-14 2013-02-13 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用
CN105456293A (zh) * 2014-09-05 2016-04-06 深圳市北科生物科技有限公司 一种用于治疗糖尿病的干细胞制剂及其制备方法

Similar Documents

Publication Publication Date Title
JP2018502579A5 (enExample)
JP2024010006A5 (enExample)
Dubey et al. Oral peptide delivery: Challenges and the way ahead
Baudin et al. Nasal high flow in management of children with status asthmaticus: a retrospective observational study
JP2015517489A5 (enExample)
US20080167230A1 (en) Methods and compositions for treating or preventing lesions of the respiratory epithelium
Gulati et al. Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects
JP2011144201A5 (enExample)
JP2010508365A5 (enExample)
Gulati et al. Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases
Fantacci et al. Pneumopericardium, pneumomediastinum, and pneumorrachis complicating acute respiratory syncytial virus bronchiolitis in children
US6592848B1 (en) Mixtures of oxygen and helium for the treatment of respiratory insufficiency
JP2016510040A5 (enExample)
Nojima et al. Plastic bronchitis in a five-year-old boy treated using extracorporeal membrane oxygenation; a case report
RU2010114008A (ru) ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ГАСТРИНА 1 И G-Pen-GRGDSPCA
HRP20190921T1 (hr) Genetski modificirane mezenhimske matične stanice koje ekprimiraju alfa-1 antitripsin (aat)
JP2020518588A5 (enExample)
JP2013528622A5 (enExample)
CN108524550B (zh) Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法
Abbasi et al. Extracorporeal life support in adults with acute respiratory failure: current evidence-based practices
Averyanov et al. Inhaled surfactant in patients with covid-19 who took high-flow oxygen: The results of a retrospective analysis
Shaikh et al. Recent trends in applications of pulmonary drug delivery: a review
Nizam et al. Takotsubo Syndrome After Liver Transplantation.
Pesic¹ et al. Current knowledge about the etiopathogenesis and therapy options for COVID-19
JP2017524732A5 (enExample)